Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Change in Account Payables (2020 - 2025)

Vivos Therapeutics' Change in Account Payables history spans 6 years, with the latest figure at -$424000.0 for Q4 2025.

  • Quarterly results put Change in Account Payables at -$424000.0 for Q4 2025, down 2027.27% from a year ago — trailing twelve months through Dec 2025 was $524000.0 (up 150.0% YoY), and the annual figure for FY2025 was $524000.0, up 150.0%.
  • Change in Account Payables for Q4 2025 was -$424000.0 at Vivos Therapeutics, down from $340000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $902000.0 in Q3 2021 to a low of -$1.4 million in Q1 2021.
  • The 5-year median for Change in Account Payables is $156500.0 (2023), against an average of $42000.0.
  • The sharpest move saw Change in Account Payables surged 321.43% in 2024, then plummeted 2027.27% in 2025.
  • Year by year, Change in Account Payables stood at $220000.0 in 2021, then soared by 248.64% to $767000.0 in 2022, then dropped by 19.69% to $616000.0 in 2023, then plummeted by 96.43% to $22000.0 in 2024, then plummeted by 2027.27% to -$424000.0 in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$424000.0, $340000.0, and $499000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.